{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:03:31Z","timestamp":1790197411687,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1038\/s41591-026-04304-x","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T10:02:09Z","timestamp":1774346529000},"page":"1745-1753","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Enhanced dynamic risk stratification of smoldering multiple myeloma"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6871-8711","authenticated-orcid":false,"given":"Floris","family":"Chabrun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3144-7919","authenticated-orcid":false,"given":"Daniel E.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1274-8177","authenticated-orcid":false,"given":"Susanna","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6226-1252","authenticated-orcid":false,"given":"Elias K.","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tulika R.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9198-8338","authenticated-orcid":false,"given":"David M.","family":"Cordas dos Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hielscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Werly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia K.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Foteini","family":"Theodorakakou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Despina","family":"Fotiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine Ivy","family":"Liacos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Kanellias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelia Collado","family":"Gisbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esperanza","family":"Martin-Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalinda","family":"Termini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5340-1818","authenticated-orcid":false,"given":"Johannes","family":"Waldschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selina J.","family":"Chavda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Ainley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo Claudio","family":"Da Vi\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"De Magistris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loredana","family":"Pettine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1014-3502","authenticated-orcid":false,"given":"Michael A.","family":"Timonian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4218-7294","authenticated-orcid":false,"given":"Jean-Baptiste","family":"Alberge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidhi","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Costello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Tobia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Phan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Lamb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Theresa","family":"Silverio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth K.","family":"O\u2019Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine R.","family":"Marinac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Nadeem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1018-5139","authenticated-orcid":false,"given":"Niccolo","family":"Bolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6487-276X","authenticated-orcid":false,"given":"Kwee","family":"Yong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7011-0286","authenticated-orcid":false,"given":"K. Martin","family":"Kort\u00fcm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7680-0819","authenticated-orcid":false,"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2390-1218","authenticated-orcid":false,"given":"Mar\u00eda-Victoria","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9183-4857","authenticated-orcid":false,"given":"Jes\u00fas F.","family":"San-Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1977-3815","authenticated-orcid":false,"given":"Bruno","family":"Paiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8191-5832","authenticated-orcid":false,"given":"Efstathios","family":"Kastritis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-3254","authenticated-orcid":false,"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4181-6922","authenticated-orcid":false,"given":"Marc S.","family":"Raab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5218-5666","authenticated-orcid":false,"given":"Lorenzo","family":"Trippa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7361-3092","authenticated-orcid":false,"given":"Irene M.","family":"Ghobrial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"4304_CR1","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar, S. V. et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 15, e538\u2013e548 (2014).","journal-title":"Lancet Oncol."},{"key":"4304_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0077-4","volume":"8","author":"A Lakshman","year":"2018","unstructured":"Lakshman, A. et al. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J. 8, 59 (2018).","journal-title":"Blood Cancer J."},{"key":"4304_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00366-3","volume":"10","author":"MV Mateos","year":"2020","unstructured":"Mateos, M. V. et al. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer J. 10, 102 (2020).","journal-title":"Blood Cancer J."},{"key":"4304_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.65","volume":"6","author":"P Ravi","year":"2016","unstructured":"Ravi, P. et al. Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma. Blood Cancer J. 6, e454 (2016).","journal-title":"Blood Cancer J."},{"key":"4304_CR5","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1038\/s41375-018-0013-4","volume":"32","author":"C Fern\u00e1ndez de Larrea","year":"2018","unstructured":"Fern\u00e1ndez de Larrea, C. et al. Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression. Leukemia 32, 1427\u20131434 (2018).","journal-title":"Leukemia"},{"key":"4304_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.76","volume":"8","author":"A de Daniel","year":"2024","unstructured":"de Daniel, A. et al. The evolving pattern of the monoclonal protein improves the IMWG 2\/20\/20 classification for patients with smoldering multiple myeloma. Hemasphere 8, e76 (2024).","journal-title":"Hemasphere"},{"key":"4304_CR7","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1200\/JCO.2009.22.2257","volume":"28","author":"J Blad\u00e9","year":"2010","unstructured":"Blad\u00e9, J. et al. Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations. J. Clin. Oncol. 28, 690\u2013697 (2010).","journal-title":"J. Clin. Oncol."},{"key":"4304_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0144-x","volume":"8","author":"S Atrash","year":"2018","unstructured":"Atrash, S. et al. Evolving changes in M-protein and hemoglobin as predictors for progression of smoldering multiple myeloma. Blood Cancer J. 8, 107 (2018).","journal-title":"Blood Cancer J."},{"key":"4304_CR9","doi-asserted-by":"publisher","first-page":"E63","DOI":"10.1002\/ajh.26062","volume":"96","author":"C Gran","year":"2021","unstructured":"Gran, C. et al. Dynamic follow-up of smoldering multiple myeloma identifies a subset of patients at high risk of progression. Am. J. Hematol. 96, E63\u2013E65 (2021).","journal-title":"Am. J. Hematol."},{"key":"4304_CR10","unstructured":"Akhlaghi, T. et al. Evaluating the effect of evolving changes in serum biomarkers on the risk of progression in smoldering multiple myeloma. American Society of Hematology https:\/\/ash.confex.com\/ash\/2023\/webprogram\/Paper180315.html (2023)."},{"key":"4304_CR11","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1046\/j.1365-2141.2003.04654.x","volume":"123","author":"L Rosi\u00f1ol","year":"2003","unstructured":"Rosi\u00f1ol, L. et al. Smoldering multiple myeloma: natural history and recognition of an evolving type. Br. J. Haematol. 123, 631\u2013636 (2003).","journal-title":"Br. J. Haematol."},{"key":"4304_CR12","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1182\/bloodadvances.2018016998","volume":"2","author":"V Wu","year":"2018","unstructured":"Wu, V. et al. Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling. Blood Adv. 2, 1470\u20131479 (2018).","journal-title":"Blood Adv."},{"key":"4304_CR13","doi-asserted-by":"publisher","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","volume":"20","author":"J Hillengass","year":"2019","unstructured":"Hillengass, J. et al. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol. 20, e302\u2013e312 (2019).","journal-title":"Lancet Oncol."},{"key":"4304_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-00980-5","volume":"14","author":"NH Abdallah","year":"2024","unstructured":"Abdallah, N. H. et al. Mode of progression in smoldering multiple myeloma: a study of 406 patients. Blood Cancer J. 14, 9 (2024).","journal-title":"Blood Cancer J."},{"key":"4304_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01159-8","volume":"14","author":"A Werly","year":"2024","unstructured":"Werly, A. et al. Patterns of progression in a contemporary cohort of 447 patients with smoldering multiple myeloma. Blood Cancer J. 14, 176 (2024).","journal-title":"Blood Cancer J."},{"key":"4304_CR16","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/s41568-024-00755-x","volume":"24","author":"DM Cordas dos Santos","year":"2024","unstructured":"Cordas dos Santos, D. M. et al. New horizons in our understanding of precursor multiple myeloma and early interception. Nat. Rev. Cancer 24, 867\u2013886 (2024).","journal-title":"Nat. Rev. Cancer"},{"key":"4304_CR17","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1182\/blood.2024023880","volume":"143","author":"H Avet-Loiseau","year":"2024","unstructured":"Avet-Loiseau, H. & Bahlis, N. J. Smoldering multiple myeloma: taking the narrow over the wide path. Blood 143, 2025\u20132028 (2024).","journal-title":"Blood"},{"key":"4304_CR18","unstructured":"Dimopoulos, M.-A. et al. Phase 3 randomized study of daratumumab monotherapy versus active monitoring in patients with high-risk smoldering multiple myeloma. American Society of Hematology https:\/\/ash.confex.com\/ash\/2024\/webprogram\/Paper201057.html (2023)."},{"key":"4304_CR19","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1182\/blood.2024025897","volume":"145","author":"O Landgren","year":"2025","unstructured":"Landgren, O. et al. Efficacy and safety of daratumumab in intermediate\/high-risk smoldering multiple myeloma: final analysis of CENTAURUS. Blood 145, 1658\u20131669 (2025).","journal-title":"Blood"},{"key":"4304_CR20","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/S1470-2045(16)30124-3","volume":"17","author":"MV Mateos","year":"2016","unstructured":"Mateos, M. V. et al. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial. Lancet Oncol. 17, 1127\u20131136 (2016).","journal-title":"Lancet Oncol."},{"key":"4304_CR21","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1200\/JCO.19.01740","volume":"38","author":"S Lonial","year":"2020","unstructured":"Lonial, S. et al. Randomized trial of lenalidomide versus observation in smoldering multiple myeloma. J. Clin. Oncol. 38, 1126\u20131137 (2020).","journal-title":"J. Clin. Oncol."},{"key":"4304_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00569-2","volume":"11","author":"A Visram","year":"2021","unstructured":"Visram, A. et al. Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis. Blood Cancer J. 11, 186 (2021).","journal-title":"Blood Cancer J."},{"key":"4304_CR23","first-page":"2739\u22122751","volume":"43","author":"H Avet-Loiseau","year":"2025","unstructured":"Avet-Loiseau, H. et al. International Myeloma Society\/International Myeloma Working Group consensus recommendations on the definition of high-risk multiple myeloma. J. Clin. Oncol. 43, 2739\u22122751 (2025).","journal-title":"J. Clin. Oncol."},{"key":"4304_CR24","doi-asserted-by":"publisher","first-page":"TPS8075","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS8075","volume":"40","author":"MA Dimopoulos","year":"2022","unstructured":"Dimopoulos, M. A. et al. Subcutaneous daratumumab (DARA SC) versus active monitoring in patients (pts) with high-risk smoldering multiple myeloma (SMM): randomized, open-label, phase 3 AQUILA study. J. Clin. Oncol. 40, TPS8075 (2022).","journal-title":"J. Clin. Oncol."},{"key":"4304_CR25","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1182\/blood-2023-177954","volume":"142","author":"O Nadeem","year":"2023","unstructured":"Nadeem, O. et al. Immuno-PRISM: a randomized phase II platform study of bispecific antibodies in high-risk smoldering myeloma. Blood 142, 206 (2023).","journal-title":"Blood"},{"key":"4304_CR26","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1038\/s41375-020-0718-z","volume":"34","author":"CO Landgren","year":"2020","unstructured":"Landgren, C. O. et al. Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS). Leukemia 34, 1840\u20131852 (2020).","journal-title":"Leukemia"},{"key":"4304_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.61","volume":"8","author":"G Mellgard","year":"2024","unstructured":"Mellgard, G. et al. Risk stratification models overestimate progression risk in contemporary patients with smoldering multiple myeloma. Hemasphere 8, e61 (2024).","journal-title":"Hemasphere"},{"key":"4304_CR28","doi-asserted-by":"publisher","first-page":"e203","DOI":"10.1016\/S2352-3026(22)00386-6","volume":"10","author":"A Cowan","year":"2023","unstructured":"Cowan, A. et al. Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study. Lancet Haematol. 10, e203\u2013e212 (2023).","journal-title":"Lancet Haematol."},{"key":"4304_CR29","doi-asserted-by":"publisher","first-page":"5512","DOI":"10.1182\/blood-2019-132260","volume":"134","author":"SU Malik","year":"2019","unstructured":"Malik, S. U. et al. Update on risk stratification model of smoldering multiple myeloma: a systematic review. Blood 134, 5512 (2019).","journal-title":"Blood"},{"key":"4304_CR30","first-page":"2736","volume":"11","author":"MA Vasco-Mogorr\u00f3n","year":"2021","unstructured":"Vasco-Mogorr\u00f3n, M. A. et al. Blood-based risk stratification for pre-malignant and symptomatic plasma cell neoplasms to improve patient management. Am. J. Cancer Res. 11, 2736\u20132753 (2021).","journal-title":"Am. J. Cancer Res."},{"key":"4304_CR31","doi-asserted-by":"publisher","first-page":"4681","DOI":"10.1002\/sim.6274","volume":"33","author":"D Jackson","year":"2014","unstructured":"Jackson, D. et al. Relaxing the independent censoring assumption in the Cox proportional hazards model using multiple imputation. Stat. Med. 33, 4681\u20134694 (2014).","journal-title":"Stat. Med."},{"key":"4304_CR32","unstructured":"National Academies of Sciences, Engineering, and Medicine. Reproducibility and Replicability in Science (National Academies Press, 2019); https:\/\/www.nationalacademies.org\/projects\/DBASSE-BBCSS-17-03 ."},{"key":"4304_CR33","doi-asserted-by":"publisher","first-page":"dju048","DOI":"10.1093\/jnci\/dju048","volume":"106","author":"M Riester","year":"2014","unstructured":"Riester, M. et al. Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples. J. Natl Cancer Inst. 106, dju048 (2014).","journal-title":"J. Natl Cancer Inst."},{"key":"4304_CR34","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris, P. A. et al. Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support. J. Biomed. Inform. 42, 377\u2013381 (2009).","journal-title":"J. Biomed. Inform."},{"key":"4304_CR35","doi-asserted-by":"publisher","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris, P. A. et al. The REDCap consortium: building an international community of software platform partners. J. Biomed. Inform. 95, 103208 (2019).","journal-title":"J. Biomed. Inform."},{"key":"4304_CR36","unstructured":"Therneau, T. M. A package for survival analysis in R. https:\/\/cran.r-project.org\/web\/packages\/survival\/vignettes\/survival.pdf (2026)."},{"key":"4304_CR37","unstructured":"R Core Team R: A Language and Environment for Statistical Computing (R Foundation for Statistical Computing, 2022); https:\/\/www.R-project.org"},{"key":"4304_CR38","doi-asserted-by":"publisher","first-page":"3362","DOI":"10.1016\/j.arth.2021.04.015","volume":"36","author":"H Maradit Kremers","year":"2021","unstructured":"Maradit Kremers, H. et al. Competing risk analysis: what does it mean and when do we need it in orthopedics research? J. Arthroplasty 36, 3362\u20133366 (2021).","journal-title":"J. Arthroplasty"},{"key":"4304_CR39","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1177\/0272989X18801312","volume":"38","author":"A Bansal","year":"2018","unstructured":"Bansal, A. & Heagerty, P. J. A tutorial on evaluating the time-varying discrimination accuracy of survival models used in dynamic decision making. Med. Decis. Making 38, 904\u2013916 (2018).","journal-title":"Med. Decis. Making"},{"key":"4304_CR40","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1177\/0962280218785504","volume":"29","author":"Debray, T. P","year":"2019","unstructured":"Debray, T. P. et al. A framework for meta-analysis of prediction model studies with binary and time-to-event outcomes. Stat. Methods Med. Res. 29, 2768\u20132787 (2019).","journal-title":"Stat. Methods Med. Res."},{"key":"4304_CR41","unstructured":"Raudenbush, S. W. in The Handbook of Research Synthesis and Meta-Analysis (eds Cooper H. et al.) 295\u2013316 (Russell Sage Foundation, 2009)."},{"key":"4304_CR42","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1002\/sim.6111","volume":"33","author":"C Combescure","year":"2014","unstructured":"Combescure, C., Foucher, Y. & Jackson, D. Meta-analysis of single-arm survival studies: a distribution-free approach for estimating summary survival curves with random effects. Stat. Med. 33, 2521\u20132537 (2014).","journal-title":"Stat. Med."},{"key":"4304_CR43","doi-asserted-by":"publisher","first-page":"5381","DOI":"10.1002\/sim.5958","volume":"32","author":"P Blanche","year":"2013","unstructured":"Blanche, P., Dartigues, J. F. & Jacqmin-Gadda, H. Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks. Stat. Med. 32, 5381\u20135397 (2013).","journal-title":"Stat. Med."},{"key":"4304_CR44","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3389\/fpubh.2017.00307","volume":"5","author":"R Trevethan","year":"2017","unstructured":"Trevethan, R. Sensitivity, specificity, and predictive values: foundations, pliabilities, and pitfalls in research and practice. Front. Public Health 5, 307 (2017).","journal-title":"Front. Public Health"},{"key":"4304_CR45","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.jclinepi.2012.03.006","volume":"65","author":"MMG Leeflang","year":"2012","unstructured":"Leeflang, M. M. G., Deeks, J. J., Rutjes, A. W. S., Reitsma, J. B. & Bossuyt, P. M. M. Bivariate meta-analysis of predictive values of diagnostic tests can be an alternative to bivariate meta-analysis of sensitivity and specificity. J. Clin. Epidemiol. 65, 1088\u20131097 (2012).","journal-title":"J. Clin. Epidemiol."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04304-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04304-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04304-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T14:02:40Z","timestamp":1779285760000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04304-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["4304"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04304-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6696313\/v1","asserted-by":"object"}]},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"assertion":[{"value":"19 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.K.M. served an advisory board member for Bristol Myers Squibb\/Celgene, GlaxoSmithKline, Janssen-Cilag, Menarini\/Stemline, Oncopeptides, Pfizer, Sanofi and Takeda; received honoraria from Bristol Myers Squibb\/Celgene, GlaxoSmithKline, Janssen-Cilag, Menarini\/Stemline, Oncopeptides, Pfizer, Sanofi and Takeda; received research funding from Bristol Myers Squibb\/Celgene, GlaxoSmithKline, Janssen-Cilag, Sanofi and Takeda; and received travel expenses from Bristol Myers Squibb\/Celgene, GlaxoSmithKline, Janssen-Cilag, Menarini\/Stemline, Pfizer, Sanofi and Takeda. D.M.C.d.S. received research funding from Regeneron. J.W. has consulted for Johnson & Johnson, Sanofi, Takeda, Pfizer, Stemline, Oncopeptides and Skyline Dx; received honoraria from Takeda, GlaxoSmithKline and BeiGene; and received research support from Bristol Myers Squibb. L.A. declares grants from the International Myeloma Society for travel and conference expenses. E.K. reports honoraria from Amgen, Janssen, Takeda, Genesis Pharma, Pfizer and GlaxoSmithKline; travel grants from Janssen; and being an advisory board member for Janssen and Prothena. M.A.D. declares honoraria from Amgen, Bristol Myers Squibb, Takeda and Janssen and is an advisory board member for Amgen, Bristol Myers Squibb, Takeda and Janssen. C.R.M. reports research funding from GRAIL. O.N. served on advisory boards for Johnson & Johnson, Bristol Myers Squibb, Sanofi, GPCR Therapeutics, Kite and AstraZeneca and received research funding from Bristol Myers Squibb, Johnson & Johnson and Takeda. N.B. received unrestricted research funding from Janssen; served on advisory boards for Takeda, Pfizer and Johnson & Johnson; and served on speakers bureaus for Johnson & Johnson, Sanofi, Amgen, Oncopeptides, Pfizer and GlaxoSmithKline. M.C.D.V. served on advisory boards for Takeda, Pfizer, Menarini\/Stemline, Amgen and Johnson & Johnson and on speakers bureaus for Johnson & Johnson, Sanofi and GlaxoSmithKline. K.M.K. received honoraria and\/or research support from AbbVie, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Novartis, Pfizer, Sanofi, Takeda and Stemline. H.E. has consulted for Bristol Myers Squibb, Johnson & Johnson, Amgen, Takeda, Sanofi, GlaxoSmithKline and Novartis; discloses research funding from Bristol Myers Squibb, Johnson & Johnson, Amgen, GlaxoSmithKline and Sanofi; has received honoraria from Bristol Myers Squibb, Johnson & Johnson, Amgen, Takeda, Sanofi, GlaxoSmithKline and Novartis; and received travel support from Bristol Myers Squibb, Johnson & Johnson, Amgen, Takeda, Novartis and Sanofi. J.F.S.-M. reports consultancy fees from AbbVie, Amgen, Bristol Myers Squibb\/Celgene, GlaxoSmithKline, Haemalogix, Janssen, Karyopharm Therapeutics, Merck Sharp & Dohme, Novartis, Regeneron, Roche, Sanofi, Secura Bio and Takeda. B.P. reports consultancy fees from Bristol Myers Squibb\/Celgene, GlaxoSmithKline, Janssen, Roche, Sanofi and Takeda; research funding from AstraZeneca, BeiGene, Bristol Myers Squibb, GlaxoSmithKline, Roche and Sanofi; and honoraria from Adaptive, Amgen, Becton Dickinson Biosciences, Bristol Myers Squibb\/Celgene, GlaxoSmithKline, Janssen, Roche and Sanofi. I.M.G. has consulted for Bristol Myers Squibb, AstraZeneca, Amgen, Curio Science, Sanofi, Johnson & Johnson, Pfizer, Menarini Silicon Biosystems, Aptitude Health, GlaxoSmithKline, AbbVie, Adaptive Biotechnologies, Window Therapeutics and Regeneron. She has received honoraria or speaker fees from Vor Biopharma, Janssen, MJH Life Sciences, Novartis, Takeda, Amgen, Regeneron, Curio Science, Standard Biotools and Physicians\u2019 Education Resource. She is a founder and executive board member of, and holds private equity in, Predicta Biosciences. Her spouse is the chief medical officer of, and holds private equity in, Disc Medicine. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}